Predictive model for the 5-year survival status of osteosarcoma patients based on the SEER database and XGBoost algorithm | Scientific Reports
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up - ESMO Open
Efficacy Results | Myelofibrosis Clinical Trials | Jakafi HCP
OA08.03 The 5-year Survival Rate of Postoperative Non-small Cell Lung Cancer Patients with Two Different Follow-up Patterns - Journal of Thoracic Oncology
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution - ecancer
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database | BMC Cancer | Full Text
Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy | In Vivo
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/5-Table2-1.png "PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar")
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
View Image
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC? - Journal of Thoracic Oncology
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
View Image
![A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2019/7837/1/fig-3-full.png "A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]")
A prognostic nomogram for overall survival in male breast cancer with histology of infiltrating duct carcinoma after surgery [PeerJ]
SciELO - Brasil - SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER SURVIVAL OF PATIENTS WITH COLORECTAL CANCER IN A CANCER CENTER
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) | Journal for ImmunoTherapy of Cancer | Full Text
This figure shows the 5-year overall survival (OS) in 250 synovial... | Download Scientific Diagram
